RCUS is down 4.21% today. Volume is 2.70M vs a 30-day average of 2.22M (1.21x).
Arcus Biosciences, Inc. is scheduled to report earnings Wed, Nov 4, 2026 · after close. Analysts expect EPS of $-0.91 on revenue of about $8.47M. Stocks often move sharply on earnings day.
HAYWARD, Calif., October 26, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combi…
Arcus Biosciences completed a US$250.0 million follow-on equity offering of 14,285,715 common shares at US$17.50 each, following recent casdatifan data updates in clear cell renal…
Arcus Biosciences has pulled back sharply in recent weeks, even though investors are still digesting fresh trial data and a sizeable equity raise. For anyone looking at the stock …
HAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combina…
Investing.com -- Arcus Biosciences Inc (NYSE:RCUS) shares dropped 6.6% in after-hours trading Wednesday following the company's announcement of an underwritten public offering of …